Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glulisine vs Aspart vs Lispro in CSII for T1D
NCT00607087Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2008
- Primary completion
- Jun 2009
- Modality
- Peptides
- Countries
- 12
01
Overview
Phase 4, randomised, open-label trial of insulin glulisine in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Sanofi. Primary endpoint: Percentage of Patients With at Least One Unexplained Hyperglycemia and/or Confirmed Infusion Set Occlusion at 13 weeks. Started Jan 2008; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00607087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607087.